CA1206077A - Dosage enzymatique de la creatinine - Google Patents

Dosage enzymatique de la creatinine

Info

Publication number: CA1206077A
Authority: CA; Canada
Prior art keywords: composition; creatinine; sarcosine; creatine; determination
Prior art date: 1983-04-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000441549A

Other languages

English (en)

Inventor

Piero Fossati

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Miles Italiana SpA

Original Assignee

Miles Italiana SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-04-18

Filing date

1983-11-21

Publication date

1986-06-17

1983-11-21 Application filed by Miles Italiana SpA filed Critical Miles Italiana SpA

1986-06-17 Application granted granted Critical

1986-06-17 Publication of CA1206077A publication Critical patent/CA1206077A/fr

Status Expired legal-status Critical Current

Links

DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 title claims abstract description 158
229940109239 creatinine Drugs 0.000 title claims abstract description 79
238000003556 assay Methods 0.000 title abstract description 13
230000002255 enzymatic effect Effects 0.000 title abstract description 5
239000000203 mixture Substances 0.000 claims abstract description 62
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 40
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims abstract description 38
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims abstract description 32
238000012360 testing method Methods 0.000 claims abstract description 32
RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims abstract description 28
238000000034 method Methods 0.000 claims abstract description 25
108010077895 Sarcosine Proteins 0.000 claims abstract description 20
229960003624 creatine Drugs 0.000 claims abstract description 20
239000006046 creatine Substances 0.000 claims abstract description 20
229940043230 sarcosine Drugs 0.000 claims abstract description 19
108010066906 Creatininase Proteins 0.000 claims abstract description 18
108010077078 Creatinase Proteins 0.000 claims abstract description 17
108010060059 Sarcosine Oxidase Proteins 0.000 claims abstract description 16
102000008118 Sarcosine oxidase Human genes 0.000 claims abstract description 16
150000002989 phenols Chemical class 0.000 claims abstract description 16
239000000243 solution Substances 0.000 claims description 23
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 19
239000012530 fluid Substances 0.000 claims description 11
102000003992 Peroxidases Human genes 0.000 claims description 9
108040007629 peroxidase activity proteins Proteins 0.000 claims description 9
239000000276 potassium ferrocyanide Substances 0.000 claims description 9
XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 claims description 9
238000006243 chemical reaction Methods 0.000 claims description 8
239000000872 buffer Substances 0.000 claims description 6
238000001514 detection method Methods 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
238000001035 drying Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000000264 sodium ferrocyanide Substances 0.000 claims description 4
235000012247 sodium ferrocyanide Nutrition 0.000 claims description 4
LWKJNIMGNUTZOO-UHFFFAOYSA-N 3,5-dichloro-2-hydroxybenzenesulfonic acid Chemical compound OC1=C(Cl)C=C(Cl)C=C1S(O)(=O)=O LWKJNIMGNUTZOO-UHFFFAOYSA-N 0.000 claims description 2
108010024957 Ascorbate Oxidase Proteins 0.000 claims description 2
GIAVHGFPMPSIFI-UHFFFAOYSA-N 3-hydroxy-2,4,6-triiodobenzoic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(O)=C1I GIAVHGFPMPSIFI-UHFFFAOYSA-N 0.000 claims 3
229940072417 peroxidase Drugs 0.000 claims 3
GTSHREYGKSITGK-UHFFFAOYSA-N sodium ferrocyanide Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] GTSHREYGKSITGK-UHFFFAOYSA-N 0.000 claims 3
239000011149 active material Substances 0.000 claims 1
102000004190 Enzymes Human genes 0.000 abstract description 10
108090000790 Enzymes Proteins 0.000 abstract description 10
210000001124 body fluid Anatomy 0.000 abstract description 8
239000010839 body fluid Substances 0.000 abstract description 8
UETZVSHORCDDTH-UHFFFAOYSA-N iron(2+);hexacyanide Chemical compound [Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] UETZVSHORCDDTH-UHFFFAOYSA-N 0.000 abstract description 3
239000013543 active substance Substances 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 description 15
229960003742 phenol Drugs 0.000 description 14
210000002966 serum Anatomy 0.000 description 14
238000002835 absorbance Methods 0.000 description 10
210000002700 urine Anatomy 0.000 description 10
150000002500 ions Chemical class 0.000 description 9
239000000126 substance Substances 0.000 description 9
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
238000011084 recovery Methods 0.000 description 7
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
239000002253 acid Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
235000012249 potassium ferrocyanide Nutrition 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
230000000694 effects Effects 0.000 description 5
239000011734 sodium Substances 0.000 description 5
230000002485 urinary effect Effects 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
240000001987 Pyrus communis Species 0.000 description 4
239000004202 carbamide Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000007598 dipping method Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000011591 potassium Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
239000012085 test solution Substances 0.000 description 3
SSIZLKDLDKIHEV-UHFFFAOYSA-N 2,6-dibromophenol Chemical compound OC1=C(Br)C=CC=C1Br SSIZLKDLDKIHEV-UHFFFAOYSA-N 0.000 description 2
DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241000589774 Pseudomonas sp. Species 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000002390 adhesive tape Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000036765 blood level Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
239000003365 glass fiber Substances 0.000 description 2
BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229940075930 picrate Drugs 0.000 description 2
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
239000007858 starting material Substances 0.000 description 2
229940116269 uric acid Drugs 0.000 description 2
239000012224 working solution Substances 0.000 description 2
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
NKTOLZVEWDHZMU-UHFFFAOYSA-N 2,5-xylenol Chemical compound CC1=CC=C(C)C(O)=C1 NKTOLZVEWDHZMU-UHFFFAOYSA-N 0.000 description 1
INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
MVRPPTGLVPEMPI-UHFFFAOYSA-N 2-cyclohexylphenol Chemical compound OC1=CC=CC=C1C1CCCCC1 MVRPPTGLVPEMPI-UHFFFAOYSA-N 0.000 description 1
KQMCGGGTJKNIMC-UHFFFAOYSA-N 2-hydroxy-3-propyl-2h-furan-5-one Chemical compound CCCC1=CC(=O)OC1O KQMCGGGTJKNIMC-UHFFFAOYSA-N 0.000 description 1
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
FFWRVGFHKDCZQI-UHFFFAOYSA-N 3,5-dibromo-2-hydroxybenzenesulfonic acid Chemical class OC1=C(Br)C=C(Br)C=C1S(O)(=O)=O FFWRVGFHKDCZQI-UHFFFAOYSA-N 0.000 description 1
CEOCHRYOARMIGS-UHFFFAOYSA-N 4,5-dichloro-2-hydroxybenzenesulfonic acid Chemical compound OC1=CC(Cl)=C(Cl)C=C1S(O)(=O)=O CEOCHRYOARMIGS-UHFFFAOYSA-N 0.000 description 1
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 1
WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
108090000531 Amidohydrolases Proteins 0.000 description 1
102000004092 Amidohydrolases Human genes 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
241000725101 Clea Species 0.000 description 1
241000186249 Corynebacterium sp. Species 0.000 description 1
101150105088 Dele1 gene Proteins 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
241000589564 Flavobacterium sp. Species 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
101710132584 Peroxidase 3 Proteins 0.000 description 1
101710132592 Peroxidase 8 Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
108010016797 Sickle Hemoglobin Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
208000010399 Wasting Syndrome Diseases 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
MVIOINXPSFUJEN-UHFFFAOYSA-N benzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=CC=C1 MVIOINXPSFUJEN-UHFFFAOYSA-N 0.000 description 1
235000012251 calcium ferrocyanide Nutrition 0.000 description 1
239000000279 calcium ferrocyanide Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003518 caustics Substances 0.000 description 1
OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
229960003012 cefamandole Drugs 0.000 description 1
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000009483 enzymatic pathway Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000013100 final test Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
229940025294 hemin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
229940091173 hydantoin Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
238000009940 knitting Methods 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
230000003387 muscular Effects 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
230000003617 peroxidasic effect Effects 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
229960003424 phenylacetic acid Drugs 0.000 description 1
239000003279 phenylacetic acid Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
231100000857 poor renal function Toxicity 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
-1 quinone compound Chemical class 0.000 description 1
239000000376 reactant Substances 0.000 description 1
229960000581 salicylamide Drugs 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
229940039790 sodium oxalate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
ZXQVPEBHZMCRMC-UHFFFAOYSA-R tetraazanium;iron(2+);hexacyanide Chemical compound [NH4+].[NH4+].[NH4+].[NH4+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] ZXQVPEBHZMCRMC-UHFFFAOYSA-R 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011282 treatment Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002023 wood Substances 0.000 description 1

Landscapes

Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA000441549A 1983-04-18 1983-11-21 Dosage enzymatique de la creatinine Expired CA1206077A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48573383A	1983-04-18	1983-04-18
US485,733		1983-04-18

Publications (1)

Publication Number	Publication Date
CA1206077A true CA1206077A (fr)	1986-06-17

Family

ID=23929251

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000441549A Expired CA1206077A (fr)	1983-04-18	1983-11-21	Dosage enzymatique de la creatinine

Country Status (1)

Country	Link
CA (1)	CA1206077A (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0291321A3 (fr) *	1987-05-14	1989-09-06	EASTMAN KODAK COMPANY (a New Jersey corporation)	Elément et procédé pour la détermination de la créatinine ou créatine
CN112029817A (zh) *	2020-07-13	2020-12-04	兰州百源基因技术有限公司	一种肌酐检测试剂盒及其使用方法
CN112074609A (zh) *	2018-05-10	2020-12-11	东洋纺株式会社	生物成分测定试剂盒的灵敏度降低抑制方法

1983
- 1983-11-21 CA CA000441549A patent/CA1206077A/fr not_active Expired

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0291321A3 (fr) *	1987-05-14	1989-09-06	EASTMAN KODAK COMPANY (a New Jersey corporation)	Elément et procédé pour la détermination de la créatinine ou créatine
CN112074609A (zh) *	2018-05-10	2020-12-11	东洋纺株式会社	生物成分测定试剂盒的灵敏度降低抑制方法
CN112074609B (zh) *	2018-05-10	2024-02-09	东洋纺株式会社	生物成分测定试剂盒的灵敏度降低抑制方法
CN112029817A (zh) *	2020-07-13	2020-12-04	兰州百源基因技术有限公司	一种肌酐检测试剂盒及其使用方法
CN112029817B (zh) *	2020-07-13	2024-02-02	兰州百源基因技术有限公司	一种肌酐检测试剂盒及其使用方法

Legal Events

Date	Code	Title	Description
2003-11-21	MKEX	Expiry
2023-05-26	MKEX	Expiry	Effective date: 20031121

Publication	Publication Date	Title
KR920001449B1 (ko)	1992-02-14	효소적산화에 의한 검체의 비색적 측정방법 및 시약
US5126247A (en)	1992-06-30	Method, system and devices for the assay and detection of biochemical molecules
US4321397A (en)	1982-03-23	4-Aminoantipyrine dye for the analytic determination of hydrogen peroxide
EP0279988B1 (fr)	1991-04-24	Système numérique de contrôle colorimétrique
US4247631A (en)	1981-01-27	Reagent and method for the analytic determination of hydrogen peroxide
CA1201369A (fr)	1986-03-04	Substrats catalyses pour le dosage colorimetrique et le dosage fluorimetrique de la peroxydase
CA1254616A (fr)	1989-05-23	Dosage enzymatique electrochimique
IE65537B1 (en)	1995-11-01	Use of a sparingly soluble salt of a heteropoly acid for the determination of an analyte a corresponding method of determination as well as a suitable agent therefor
JPH0470000B2 (fr)	1992-11-09
US4416983A (en)	1983-11-22	Determination of NAD(P)H or salicylate
EP0133681B1 (fr)	1988-09-14	Essai enzymatique d'urée
EP0606296B1 (fr)	1999-03-03	Reactifs et methodes de dosage comportant un indicateur contenant de la phenazine
Cohenford et al.	1989	Colorimetric assay for free and bound L-fucose
EP0206316B1 (fr)	1991-04-10	Méthode et composition d'essai pour la détermination du peroxyde d'hydrogène
JP2005118014A (ja)	2005-05-12	分析方法およびそれに用いる試薬
EP0193204B1 (fr)	1990-06-27	Procédé pour la détermination de l'activité de la dismutase superoxyde
WO1989005356A1 (fr)	1989-06-15	Determimation quantitative de salicylates ou nucleotides de pyridine reduits
Kayamori et al.	1997	Enzymatic method for assaying uric acid in serum with a new tetrazolium salt produces water-soluble formazan dye
US5188941A (en)	1993-02-23	Enzymatic determination of theophylline
US5487978A (en)	1996-01-30	Method, composition and device for the determination of cholesterol using cholesterol oxidase obtained from bacterial strain NRRL B-18713
EP0159513A1 (fr)	1985-10-30	Dosage enzymatique du phosphate inorganique
US5919644A (en)	1999-07-06	Method for assaying sulfate-conjugated bile acid and therefore
CA1339794C (fr)	1998-04-07	Determination enzymatique de la theophylline
JPS6342519B2 (fr)	1988-08-24
AU626724B2 (en)	1992-08-06	Enzymatic determination of theophylline